Three years ago, Moderna, flush with cash from Covid vaccine sales, announced it would start investing in the burgeoning field of gene editing. It created a new division called Moderna Genomics and struck a collaboration with Metagenomi, a new startup specializing in developing new gene-editing enzymes.
“This will be a completely new approach for Moderna and a dramatic expansion of our modality strategy,” Moderna president Stephen Hogue told investors.
Those efforts appear to have hit some road bumps. On Wednesday, Metagenomi announced the two companies broke off the collaboration after three years of research. The startup said the decision was “mutual” but also attributed it to a “strategic prioritization” by Moderna.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect